medcelerator · clinician one-pager
New Oral Medicine to Help Prevent COVID-19 After Exposure
Xocova / Zokovea (ensitrelvir) — oral COVID-19 post-exposure prophylaxis
FDA Approved · United States, Japan · September 7, 2026
Condition: COVID-19
Who this is for
Xocova (ensitrelvir) is the first pill approved in the United States to help prevent COVID-19 after contact with someone who has it. It is for people 12 and older, started within 72 hours.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States and Japan, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220442Orig1s000lbl.pdf
Japan · Prescription
Japan prescription (Xocova, PMDA-approved)
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
jRCT (Japan Registry of Clinical Trials)
Japan Registry of Clinical Trials, the public registry used under Japanese clinical-trial rules. Search studies by condition and location. A jRCT listing is not PMDA approval and is not enrolment.
https://jrct.mhlw.go.jp/en-top
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/xocova-ensitrelvir